Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome, GSK Agree on Possible Use of DNA Methylation Biomarker

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OncoMethylome Sciences today announced an agreement with GlaxoSmithKline Biologics for the potential use of a DNA methylation-specific biomarker for the development of immunotherapeutics.

The two firms began a collaboration in 2007, and today's agreement "marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK," said Jan Groen, CEO of OncoMethylome. He added that it "underpins our strategy of leveraging our methylation-specific PCR platform" for the development of companion diagnostics and personalized medicine.

The biomarker, the Belgian company said, allows for the analysis of non-invasive tissue samples.

Financial terms of the agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more